Cash Flow Statement (Annual)

CVSI / CV Sciences, Inc. Cash Flow Statement shows changes in cash positions over time. Cash Flow Statement data includes Cash from Operating Activities (CFOP), Cash from Investing Activities, and Cash from Financing Activities.

All numbers are times 1,000 except per share units.

2011 2012 2013 2014 2015 2016 2017
Net Cash Provided By Used In Operating Activities
  Net Income Loss -90 -46 -2,300 -1,312 -12,233 -14,141 -4,897
  Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
    Depreciation Depletion And Amortization - - - 934 1,012 1,053 183
    Depreciation And Amortization - 0 767 934 - - -
    Amortization Of Financing Costs - - - 0 265 289 220
    Amortization Of Debt Discount Premium - 0 211 589 - - -
    Amortization Of Derivative Liability Discount - - - - 0 408 29
    Stock Issued Pursuant To Employment Agreement - - 6 42 0 - -
    Issuance Of Stock And Warrants For Services Or Claims - - - 0 328 541 0
    Amortization Of Beneficial Conversion Feature Of Convertible Debt - - - 589 574 0 -
    Income Loss From Equity Method Investments - 0 -311 -39 0 - -
    Restricted Shares Issued Under Employment Agreement Amount - 0 -6 - - - -
    Gain Loss On Sale Of Equity Investments - - 0 7,899 0 - -
    Share Based Compensation - - 0 7,916 5,720 2,733 3,420
    Royalty Expense - - - - - 0 2,432
    Note Receivable Issued On Litigation Settlement - - - 0 600 0 -
    Increase Decrease In Other Operating Assets - - 0 -35 0 - -
    Provision For Doubtful Accounts - 0 400 -300 2,655 59 483
    Increase Decrease In Deferred Income Taxes - - - - - 0 482
    Allowance For Doubtful Accounts Receivable Period Increase Decrease - - - -300 2,655 - -
    Increase Decrease In Interest Payable Net - - - - 0 128 189
    Fair Value Adjustment Of Warrants - - - - - 0 137
    Derivative Gain Loss On Derivative Net - - - - 0 147 249
    Gain Loss On Disposition Of Assets - - - - 0 -9 -12
    Gain On Collection Of Related Party Notes Receivable - - - - 0 379 0
    Gain Loss On Derivative Instruments Net Pretax - - - - - 147 249
    Inventory Write Down - - - - 0 3,562 0
    Goodwill And Intangible Asset Impairment - - 0 0 0 2,747 0
  Increase Decrease In Operating Capital
    Increase Decrease In Prepaid Expense -2 2 174 353 -76 - -
    Increase Decrease In Accounts Payable 20 -20 25 191 113 - -
    Increase Decrease In Other Accrued Liabilities - 0 223 179 418 - -
    Net Cash Provided By Used In Operating Activities Continuing Operations - -64 -4,879 -6,712 -4,208 -2,054 -
    Increase Decrease In Prepaid Expenses Other - - - - -520 0 -
    Increase Decrease In Accounts Receivable - 0 1,744 -1,206 588 -70 1,241
    Increase Decrease In Notes Receivable Current - - - - - 0 25
    Increase Decrease In Inventories - 0 2,128 9,193 2,468 -1,309 -1,043
    Increase Decrease In Prepaid Deferred Expense And Other Assets - 0 474 -1,215 -520 -61 401
    Increase Decrease In Accounts Payable And Accrued Liabilities - - - - 531 -355 1,780
    Increase Decrease In Deferred Revenue And Customer Advances And Deposits - - - - - 0 981
  Net Cash Provided By Used In Operating Activities -80 -64 - - - -2,054 3,615
Net Cash Provided By Used In Investing Activities
  Cash Acquired From Acquisition - 0 51 0 - - -
  Payments For Proceeds From Longterm Investments - 0 950 0 - - -
  Payments To Acquire Equity Method Investments - 0 750 0 - - -
  Net Cash Provided By Used In Investing Activities Continuing Operations - 0 -1,876 -1,384 -1,743 853 -
  Payments To Acquire Businesses Gross - - - 0 250 0 -
  Payments To Acquire Notes Receivable - - 0 1,200 2,003 0 -
  Proceeds From Collection Of Notes Receivable Related Party - - - - 0 859 -
  Repayment Of Principal On Note Receivable - - 0 265 - - -
  Repayment Of Notes Receivable - - - 265 624 - -
  Proceeds From Collection Of Notes Receivable - - - - 624 0 0
  Proceeds From Sale Of Property Plant And Equipment - - - - 0 10 0
  Payments To Acquire Property Plant And Equipment - 0 227 449 114 17 455
  Payments To Tenantleasehold Incentive - - - - - 0 1,546
  Net Cash Provided By Used In Investing Activities - - - - - 853 -2,000
Net Cash Provided By Used In Financing Activities
  Proceeds From Repayments Of Related Party Debt - 63 0 - - - -
  Proceeds From Related Party Debt 21 63 6,192 - - - -
  Repayment Of Loan To Roen Ventures - 0 100 - - - -
  Repayments Of Related Party Debt 0 0 0 0 0 - -
  Common Stock To Be Issued Cash Flow - 0 175 0 - - -
  Proceeds From Issuance Or Sale Of Equity - 0 2,731 - - - -
  Proceeds From Issuance Of Common Stock 29 - 2,731 8,248 2,520 0 -
  Net Cash Provided By Used In Financing Activities Continuing Operations - 63 8,998 8,155 4,167 1,740 -
  Proceeds From Notes Payable - - 6,192 0 178 - -
  Cash And Cash Equivalents Period Increase Decrease -30 -1 2,243 59 - - -
  Cash And Cash Equivalents At Carrying Value 1 - 2,244 2,302 - - -
  Issuance Of Note Payable From Vendor - - - - 178 0 -
  Proceeds From Issuance Of Unsecured Debt - - - - 0 801 0
  Repayments Of Other Debt - - - 92 0 - -
  Proceeds From Convertible Debt - - - 0 1,508 1,975 750
  Payments For Proceeds From Previous Acquisition - - - - 0 250 0
  Repayments Of Convertible Debt In Cash - - - - - 0 472
  Repayments Of Convertible Debt - - - - 0 612 0
  Repayments Of Notes Payable - - 100 92 39 174 159
  Net Cash Provided By Used In Financing Activities 50 63 - - - 1,740 119
  Cash Period Increase Decrease - - - 59 -1,784 539 1,734
  Cash - - - - 518 782 2,013
  Cash And Restricted Cash - - - - - 1,057 2,792
Noncash Investing And Financing Items
  Value Of Debt Discount - 0 800 0 - - -
  Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Receivables - - 396 0 - - -
  Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Inventory - - 345 0 - - -
  Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Prepaid Expense And Other Assets - - 1,261 0 - - -
  Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment - - 1 0 - - -
  Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Indefinite Lived Intangible Assets - - 4,110 0 - - -
  Goodwill - - 1,856 1,856 4,644 2,788 2,788
  Stock Issued During Period Value Acquisitions - 0 7,070 0 1,150 - -
  Goodwill Non Cash Transaction - - 1,856 0 - - -
  Conversion Of Convertible Promissory Notes And Accrued Interest To Common Stock - - - - 765 583 1,805
  Goodwill Acquired In Canx Acquisition - - - 0 2,538 0 -
  Intangible Asset Acquired In Canx Acquisition - - - 0 3,907 0 -
  Value Of Warrants Issued With Unsecured Promissory Note - - - - 0 267 0
  Amount Due To Phytosphere Agreement - - -1,315 0 - - -
  Contingent Consideration On Canx Acquisition - - - 0 -3,739 0 -
  Value Of Embedded Derivative At Inception - - - - 0 370 29
  Common Shares Issued On Canx Acquisition - - - 0 -1,150 0 -
  Conversion Of Line Of Credit Roen Ventures Llc To Common Stock - - 0 6,000 0 - -
  Deferred Tax Liability On Canx Acquisition - - - 0 -1,556 0 -
  Conversion Of Accounts Receivable To Note Receivable - - 0 -600 0 - -
  Equity Consideration For Royalty Buyout - - - - - 0 2
  Accrual For Required Stock Redemption - - - - 0 75 75
  Beneficial Conversion Feature On Convertible Debt - - - 0 -612 0 -
  Common Stock To Be Issued Other - - 0 -175 0 - -
  Conversion Of Convertible Promissory Notes - - - 0 765 - -
  Common Stock Received In Exchange For Sale Of Investment - - 0 8,300 0 - -
  Issuance Of Common Stock To Settle Restricted Stock Units - - - - - 0 0
  Common Stock Received In Exchange For Payment On Notes Receivable - - - 0 242 0 -
  Shares Issued In Exchange For Purchase Of Inventory - - - - - 0 202
  Common Stock Issued For Services - - - 0 -88 0 -
  Purchase Of Insurance Through Issuance Of Note Payable - - - - 0 161 149
  Common Stock Issued For Accrued Interest - - - 0 -13 0 -
  Inventory Returned In Satisfaction Of Note Receivable - - - - 0 68 0
  Contingent Equity Consideration Issued To Can X - - - - 0 0 0
  Shares Cancelled Upon Foreclosure Of Notes Receivable Value - - - - 0 60 0
Supplemental Cash Flow Information
  Interest Paid 0 3 0 187 0 338 -
  Interest Paid Net - - - - - 338 183
  Income Taxes Paid - 0 0 0 0 22 44

Peers - Cannabis and Medical Marijuana Dispensaries (512227)

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

CUSIP: 126654102